The abstract is read at the publisher; the summary is JClub's.
In the FOURIER trial of 25,090 stable ASCVD patients, low baseline lipoprotein(a) showed no association with incident haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including ≤13 nmol/L.
- Why it matters: Because Lp(a) is linked to atherogenesis and Lp(a)-lowering therapies are being tested, it is clinically important to know whether very low Lp(a) levels carry safety risks.
- What they did: FOURIER randomized 27,564 patients with stable ASCVD to evolocumab or placebo on background statins, and assessed baseline Lp(a) (median 37 nmol/L, IQR 13–165) for associations with safety outcomes using adjusted models.
- The result: Lower baseline Lp(a) was associated with higher prevalent and incident diabetes mellitus risk (adjusted OR 1.03, 95% CI 1.02–1.04; adjusted HR 1.05, 95% CI 1.02–1.08), while evolocumab did not increase DM risk by baseline Lp(a).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.